NYSEAMERICAN:CANF - CAN-FITE BIOPHA/S Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.38 +0.01 (+0.73 %) (As of 11/19/2018 03:05 AM ET)Previous Close$1.38Today's Range$1.34 - $1.3852-Week Range$1.12 - $2.75Volume33,835 shsAverage Volume150,105 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases, as well as sexual dysfunction. The company's lead drug candidate is CF101 (Piclidenoson), which is in Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis. It also develops CF102 (Namodenoson) that is in Phase II clinical trials for the treatment of liver cancer and non-alcoholic fatty liver diseases, as well as for hepatocellular carcinoma and hepatitis C virus diseases; and CF602, which is in pre-clinical trial for the treatment of sexual dysfunction. Can-Fite BioPharma Ltd. was founded in 1994 and is headquartered in Petah-Tikva, Israel. Receive CANF News and Ratings via Email Sign-up to receive the latest news and ratings for CANF and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSEAMERICAN Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNYSEAMERICAN:CANF Previous Symbol CUSIPN/A Webwww.canfite.co.il Phone+972-3-9241114 Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book ValueN/A Price / BookN/A Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous Employees7 Outstanding Shares19,980,000Market Cap$0.00 OptionableOptionable CAN-FITE BIOPHA/S (NYSEAMERICAN:CANF) Frequently Asked Questions What is CAN-FITE BIOPHA/S's stock symbol? CAN-FITE BIOPHA/S trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CANF." How were CAN-FITE BIOPHA/S's earnings last quarter? CAN-FITE BIOPHA/S (NYSEAMERICAN:CANF) posted its quarterly earnings results on Friday, August, 31st. The biotechnology company reported ($0.06) EPS for the quarter. The biotechnology company had revenue of $0.27 million for the quarter, compared to analyst estimates of $2 million. View CAN-FITE BIOPHA/S's Earnings History. When is CAN-FITE BIOPHA/S's next earnings date? CAN-FITE BIOPHA/S is scheduled to release their next quarterly earnings announcement on Monday, November 26th 2018. View Earnings Estimates for CAN-FITE BIOPHA/S. What price target have analysts set for CANF? 2 equities research analysts have issued twelve-month price targets for CAN-FITE BIOPHA/S's stock. Their forecasts range from $7.00 to $8.00. On average, they expect CAN-FITE BIOPHA/S's share price to reach $7.50 in the next twelve months. This suggests a possible upside of 443.5% from the stock's current price. View Analyst Price Targets for CAN-FITE BIOPHA/S. What is the consensus analysts' recommendation for CAN-FITE BIOPHA/S? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CAN-FITE BIOPHA/S in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CAN-FITE BIOPHA/S. What are Wall Street analysts saying about CAN-FITE BIOPHA/S stock? Here are some recent quotes from research analysts about CAN-FITE BIOPHA/S stock: 1. HC Wainwright analysts commented, "We also note that Namodenoson has both Track status in the hepatocellular carcinoma (HCC) indication. Namodenoson could be approved based on this study. The trial is a Phase 2 study, but given the unmet medical need, if the data is strong enough, it could be used as a registrational study. For this reason and for ethical reasons, management has been advised not to alter the original study design (statistical plan)." (10/31/2018) 2. Maxim Group analysts commented, "While we anticipated CanFite would need to raise capital we did not anticipate the added dilution announced in today’s raise and the potential impact of raising too little capital which sets up additional dilution." (3/9/2018) Has CAN-FITE BIOPHA/S been receiving favorable news coverage? Press coverage about CANF stock has been trending somewhat positive recently, according to InfoTrie Sentiment. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. CAN-FITE BIOPHA/S earned a daily sentiment score of 2.0 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the near term. Are investors shorting CAN-FITE BIOPHA/S? CAN-FITE BIOPHA/S saw a increase in short interest in October. As of October 31st, there was short interest totalling 356,891 shares, an increase of 11.7% from the October 15th total of 319,636 shares. Based on an average daily volume of 63,322 shares, the short-interest ratio is presently 5.6 days. View CAN-FITE BIOPHA/S's Current Options Chain. Who are some of CAN-FITE BIOPHA/S's key competitors? Some companies that are related to CAN-FITE BIOPHA/S include 22nd Century Group (XXII), 4d Pharma (DDDD), Abattis Bioceuticals (ATTBF), Abcam (ABC), ABcann Global (ABCN), ABLYNX NV/ADR (ABLX), ABZENA/PAR VTG FPD 0.002 (ABZA), Acasti Pharma (ACST), Acrux (ACR), Actinium Pharmaceuticals (ATNM), Almirall (LBTSF), Altimmune (ALT), Ampio Pharmaceuticals (AMPE), Ampliphi Biosciences (APHB) and Antibe Therapeutics (ATE). Who are CAN-FITE BIOPHA/S's key executives? CAN-FITE BIOPHA/S's management team includes the folowing people: Dr. Ilan Cohn, Co-Founder & Chairman (Age 64)Prof. Pnina Fishman, Scientific Founder, CEO & Director (Age 70)Mr. Motti Farbstein, Chief Operating & Financial Officer (Age 54)Dr. Sari Fishman Ph.D., VP of Bus. Devel. (Age 46)Dr. Michael H. Silverman M.D., F.A.C.P., FACR, Medical Director (Age 70) How do I buy shares of CAN-FITE BIOPHA/S? Shares of CANF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is CAN-FITE BIOPHA/S's stock price today? One share of CANF stock can currently be purchased for approximately $1.38. What is CAN-FITE BIOPHA/S's official website? The official website for CAN-FITE BIOPHA/S is http://www.canfite.co.il. How can I contact CAN-FITE BIOPHA/S? CAN-FITE BIOPHA/S's mailing address is 10 Bareket Street, Kiryat Matalon P.O. Box 7537, PETAH TIKVA, 49170, Israel. The biotechnology company can be reached via phone at +972-3-9241114. MarketBeat Community Rating for CAN-FITE BIOPHA/S (NYSEAMERICAN CANF)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 121 (Vote Outperform)Underperform Votes: 89 (Vote Underperform)Total Votes: 210MarketBeat's community ratings are surveys of what our community members think about CAN-FITE BIOPHA/S and other stocks. Vote "Outperform" if you believe CANF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CANF will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 11/19/2018 by MarketBeat.com StaffFeatured Article: What does earnings per share mean?